
Synthetic α-MSH analog — activates melanocortin receptors (MC1R/MC4R) — research areas: melanogenesis, energy balance, sexual signaling.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Melanotan II is a synthetic cyclic heptapeptide — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 — designed in the 1980s at the University of Arizona by Victor Hruby's and Mac Hadley's groups as a superpotent, stable analog of α-melanocyte-stimulating hormone (α-MSH). The ring formed by a lactam bond between aspartate and lysine, together with the D-phenylalanine, gives it peptidase resistance and melanocortin-receptor affinity far above those of the natural hormone.
It is a non-selective agonist: it activates MC1R on melanocytes, responsible for eumelanin synthesis and the darkening of skin and moles, but also MC3R and MC4R in the central nervous system, involved in appetite, erectile function and nausea. It was precisely in early Melanotan II trials as a tanning agent that spontaneous erections were observed, a finding that led to the development of PT-141 (bremelanotide), its MC4R-selective metabolite.
It never completed clinical development and is not approved in any country; the molecule that did reach approval via MC1R is afamelanotide (Scenesse), a linear analog indicated for erythropoietic protoporphyria. Regulatory agencies in several countries have issued warnings about Melanotan II over published cases of melanoma, darkening and changing moles, rhabdomyolysis and priapism, and over how often grey-market product is mislabeled. Renova distributes it for research only.
| Class | Synthetic cyclic α-MSH analog, non-selective melanocortin agonist |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 (7 aa; Asp–Lys lactam bridge) |
| CAS | 121062-08-6 |
| Origin | University of Arizona (Hruby, Hadley), 1980s |
| Receptors | MC1R (pigmentation), MC3R and MC4R (CNS: appetite, erectile function, nausea), MC5R |
| Relation to PT-141 | Bremelanotide is its free-C-terminus metabolite, MC4R-selective |
| Regulatory status | Never approved; regulatory-agency warnings; the approved MC1R analog is afamelanotide (Scenesse) |
| Published safety signals | Darkening and changing moles, melanoma (case reports), nausea, rhabdomyolysis, priapism |
PT-141 (bremelanotide) is the metabolite of Melanotan II with a free carboxyl terminus instead of the amide. That minimal change makes it MC4R-selective and strips away almost all of MC1R's pigmentary action. Melanotan II activates both: it tans and acts in the central nervous system at the same time.
Because the MC1R receptor it stimulates is on every melanocyte, including those in nevi. The literature contains cases of moles that darkened, grew or changed, and cases of melanoma in users, which has prompted regulatory-agency warnings. Any new or changing mole in that context requires dermatological evaluation.
No. Its clinical development was abandoned. The α-MSH analog that was approved is afamelanotide (Scenesse), a different linear peptide indicated only for erythropoietic protoporphyria. Melanotan II is a research compound worldwide.
That it activates several melanocortin receptors at once: MC1R in the skin and MC3R/MC4R in the brain. That is why its observed effects span pigmentation, reduced appetite, erections and nausea. Later analogs (PT-141, afamelanotide) were designed to keep only one of those receptors.
Related reading: Melanotan II: Melanocortin Agonist · PT-141 (Bremelanotide): A Melanocortin Receptor Agonist
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty